The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: Increased aripipirazole dose and maintenance period

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 6, 2008, Pages 721-729

  Lile, Joshua A ^a   Stoops, William W ^a   Hays, Lon R ^a,c   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aripiprazole; Cocaine; Pharmacotherapy; Physiological effects; Subjective effects

Indexed keywords

ARIPIPRAZOLE; COCAINE;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; MAINTENANCE THERAPY; MALE; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; COCAINE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PIPERAZINES; QUINOLONES;

EID: 56549099373     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802308262     Document Type: Article

References (23)

1. de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: A systematic review. Addict 2002; 97(8):931-949.
2. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology 2005; 30(11):2103-2114.
3. Stoops WW, Lile JA, Lofwall MR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 2007; 33(6):769-776.
4. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164(1):160-162.
5. 2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 2007; 32(10):2238-2247.
6. 2 receptors. J Pharmacol Exp Ther 2002; 302(1):381-389.
7. Childress AR, O'Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci 2000; 21(1):6-9.
8. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 1992; 261(3):885-894.
9. Dudish-Poulsen SA, Hatsukami DK. Dissociation between subjective and behavioral responses after cocaine stimuli presentations. Drug Alcohol Depend 1997; 47(1):1-9.
10. Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL, Bigelow GE. Development of a subject-rated rating scale sensitive to acute cocaine administration. In Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting. Harris L, ed. Rockville, MD: National Institute on Drug Abuse Research Monograph Series, 1998; 139.
11. Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306(1):195-204.
12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676.
13. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
14. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39(11):1172-1177.
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19.
16. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9):763-771.
17. Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology 2008; 199(3):403-419.
18. Pulvirenti L, Balducci C, Piercy M, Koob GF. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 1998; 286(3):1231-1238.
19. LeDuc PA, Mittleman G. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology 1993; 110(4):427-436.
20. Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 2006; 84(2):206-209.
21. Letite JV, Guimarães FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008; 578(2-3):222-227.
22. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol 2005; 25(4):363-366.
23. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66(6):756-760.